Temozolomide (TMZ) CAS 85622-93-1 Assay 99.0%~101.0% API Factory Maʻemaʻe Kiʻekiʻe
Hāʻawi i ka Temozolomide a me nā mea pili i waena:
Temozolomide CAS: 85622-93-1
4(5)-Amino-5(4)-Imidazolecarboxamide CAS: 360-97-4
5(4)-Amino-4(5)-Imidazolecarboxamide Hydrochloride CAS: 72-40-2
| Inoa Kimia | ʻO Temozolomide |
| Nā huaʻōlelo like | 3,4-Dihydro-3-Methyl-4-Oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-Carboxamide |
| Helu CAS | 85622-93-1 |
| Helu CAT | RF-API29 |
| Kūlana Kūʻai | Ma ka waihona, hoʻonui ʻia a hiki i nā tona |
| ʻĀpana Molekala | C6H6N6O2 |
| Kaumaha Molecular | 194.15 |
| Lae hehee | 212 ℃ Dek. |
| Brand | Kemika Ruifu |
| 'ikamu | Nā kikoʻī |
| Ka nana aku | Keʻokeʻo a ʻulaʻula ʻulaʻula |
| ʻIkepili | Na IR, HPLC |
| Nā mea hoʻoheheʻe koena | Dimethyl Sulphoxide ≤0.50% |
| Na mea pili | |
| haumia AIC | ≤0.10% |
| Hoʻokahi haumia | ≤0.10% |
| Hoʻomaha i nā haumia ʻike ʻole ʻia | ≤0.30% |
| Huina paumaele | ≤0.30% |
| Nā Metala Kaumaha | ≤10ppm |
| Nalo ma ka maloo | ≤0.50% |
| Koena ma ka Ignition | ≤0.10% |
| Hoʻāʻo | 99.0%~101.0% (HPLC ma ke kumu maloʻo) |
| Kūlana hoʻāʻo | Kūlana ʻoihana |
| Hoʻohana | Mea Hana Lapaʻau Hoʻoikaika (API) |
Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, pahu pahu pahu, 25kg / pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;Palekana mai ka malamalama, ka ma'ū a me ka pest infestation.
ʻO Shanghai Ruifu Chemical Co., Ltd. ka mea hana nui a me ka mea hoʻolako o Temozolomide (CAS: 85622-93-1) me ke kūlana kiʻekiʻe.ʻO Temozolomide (TMZ) he mea hoʻohana alkylating waha i hoʻohana ʻia e mālama iā Glioblastoma Multiforme (GBM) a me Astrocytomas, Metastatic Melanoma.
ʻO Temozolomide ka lāʻau anticancer mua loa i lawe ʻia ma ka waha a me ka tetrazine-class anticancer lāʻau no ka lua o ka hanauna o kahi alkylating agent me ka hana antitumor me ka ʻole o ka hoʻoulu ʻana o ka metabolic ate ma hope o ka lawelawe waha.Hōʻike ʻia ia e ke komo maʻalahi ma o ka pale koko-lolo, ka hoʻomanawanui maikaʻi a ʻaʻole i hoʻopili ʻia me nā lāʻau lapaʻau ʻē aʻe, a me ka hopena synergistic me ka radiotherapy i kūpono no ka mālama ʻana i ka hoʻi hou ʻana o ka glioma ma hope o ka mālama maʻamau e like me ka glioblastoma multiforme tumors a me ka degenerative astrocytoma.ʻO ia ka lāʻau lapaʻau mua no ka mālama ʻana i ka melanoma metastatic.
Ua hana mua ʻia ʻo Temozolomide e Cancer Research UK Group, a laila e hoʻoneʻe ʻia i ka Schering-Plough Company (United States) no ka hoʻomohala ʻana.Loaʻa iā ia kahi hanana kemika hou a pili i ka derivative ʻehā-imidazole.I ka makahiki 1999, ua ʻae ʻia no ke komo ʻana i ka mākeke ma EU a me US kahi i ʻae ʻia ai ka hōʻailona ma ʻAmelika Hui Pū ʻIa no ka lāʻau lua o ka glioblastoma multiforme a me ka degenerative star gliomas a me nā hōʻailona ʻae ʻia o EU no ka mālama ʻana i ka hoʻomohala ʻana a i ʻole ka hoʻihoʻi ʻana i ka glioblastoma multiforme. ka mea i hoʻopaʻa ʻia i ka lāʻau maʻamau.ʻO ka maikaʻi o ka temozolomide i ka mālama ʻana i ka glioblastoma multiforme ua loaʻa hou ka ʻike ma ʻEulopa.
